<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>2577484</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>L칩pez de la Torre Casares, M</dc:author>
<dc:author>Alarc칩n Alacio, J</dc:author>
<dc:author>Gonz치lez Gonz치lez, M C</dc:author>
<dc:author>Moreno Esteban, B</dc:author>
<dc:description xml:lang="en">Multiple endocrine neoplasia type I (men I) associates hyperparathyroidism with pancreatic tumors. The evaluation included the patient and its family, periodically. A good patient medical history, biochemical blood tests, carried out regularly and in an organised fashion, brings to the fore the diagnosis without difficulties. Tumoral markers are now being considered an important test for diagnosis and follow-up (gastrin, pancreatic peptid, prolactin...). The newest chromogranin is a polypeptidic group which increases in the blood of patients with endocrine neoplasias (including hyperparathyroidism and tumors of pancreatic islet cells). The specific neural enolase is increase in pancreatic islet cells tumor. The evaluation of S-100 substance, 7-B2 protein, neurotensin, alpha sub-unit of chorionic gonadothrophin and other markers will soon be of help in the diagnosis of men I.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1989 Dec </dc:date>
<dc:title xml:lang="es">MEN I: Screening de pacientes y nuevos marcadores tumorales.</dc:title>
<dc:title xml:lang="en">[MEN I (multiple endocrine neoplasia): patient screening and new tumor markers].</dc:title>
<dc:publisher>Anales de medicina interna (Madrid, Spain : 1984)</dc:publisher>
</metadata>
</record>
</pubmed-document>
